- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03431805
TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery (TRAAP2)
TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery :a Multicenter Randomised, Double Blind Placebo Controlled Trial (TRAAP2)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Regarding the prevention of PPH, recent randomized controlled trials (RCTs) of unclear quality have suggested that TXA may reduce blood loss and maternal morbidity, while a Cochrane Collaboration review has concluded, that "TXA (in addition to uterotonic medications) decreases postpartum blood loss and prevents PPH and blood transfusions following vaginal birth and CS in women at low risk of PPH based on studies of mixed quality. Further investigations are needed on efficacy and safety of this regimen for preventing PPH.
Treatment, that is a 10-mL blinded vial of the study drug (either 1g TXA or placebo according to the randomization sequence), will be administered intravenously to the participant women during the third stage of labor of cesarean delivery.
The follow-up visit will take place in the postpartum ward of the maternity unit, on D2 postpartum. This stage will include a venous blood sample to measure plasma concentrations of Hb and Ht, urea and creatinemia, prothrombin time (PT), active prothrombin time (aPTT), aspartate and alanine transaminase, total bilirubin and fibrinogen, and the completion of a self-questionnaire about satisfaction by the women, as well as the assessment of the adverse events.
At 8 weeks postpartum, a self-questionnaire assessing psychological status and well-being will be sent to the women. At 12 weeks postpartum, all participants will be contacted by phone to assess the incidence of thrombotic and any other significant events.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49033
- CHU Angers
-
Besançon, France, 25000
- CHU Jean Minjoz
-
Bordeaux, France, 33076
- CHU Bordeaux
-
Caen, France, 14033
- CHRU Côte de Nacre
-
Clermont Ferrand, France, 63001
- CHU Estain
-
Créteil, France
- Centre Hospitalier Intercommunal de Créteil
-
Marseille, France, 13008
- Hôpital Saint Joseph Marseille
-
Marseille, France, 13915
- Hopital Nord
-
Montpellier, France, 34295
- CHU de Montpellier
-
Nancy, France, 54000
- CHRU de Nancy
-
Nantes, France, 44093
- CHU Nantes
-
Nîmes, France, 30900
- CHU Nîmes
-
Paris, France, 75012
- Hôpital Trousseau
-
Paris, France, 75014
- Hopital Saint Joseph Paris
-
Paris, France, 75014
- Maternité de Port-Royal Paris
-
Paris, France, 75015
- Hopital universitaire Necker-Enfants Malades
-
Paris, France, 75019
- Hopital Universitaire Robert Debre
-
Paris, France, 94270
- Hôpital universitaire Kremlin-Bicètre
-
Pau, France
- CH de Pau
-
Poissy, France, 78303
- Centre Hospitalier Intercommunal Poissy-Saint Germain
-
Rennes, France, 35033
- CHU Rennes
-
Rouen, France, 76000
- CHU Charles Nicolle
-
Saint Etienne, France, 42270
- CHU Saint Etienne
-
Strasbourg, France, 67098
- CHU Strasbourg
-
Toulouse, France, 31059
- Hôpital Paule de Viguier CHU Toulouse
-
Tours, France, 37044
- Chu Tours
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- : adult women admitted for a cesarean delivery before or during labor, at a term ≥ 34 weeks,
- hemoglobin level at the last blood sample >9g/dl,
- available blood test for Hb and Ht within one week before caesarean delivery,
- informed signed consent
Exclusion Criteria:
- previous thrombotic event or preexisting pro-thrombotic disease,
- epileptic state or history of seizures,
- presence of any chronic or active cardiovascular disease outside hypertension,
- any chronic or active renal disease and chronic or active liver disease at risk thrombotic or hemorrhagic, autoimmune disease,
- sickle cell disease,
- placenta praevia,
- placenta accreta/increta/percreta,
- abruption placentae,
- eclampsia,
- HELLP syndrome,
- significant hemorrhage before cesarean section
- in utero fetal death,
- administration of low-molecular-weight heparin or antiplatelet agents during the week before delivery,
- planned general anesthesia,
- hypersensitivity to tranexamic acid or concentrated hydrochloric acid,
- instrumental extraction failure,
- multiple pregnancy with vaginal delivery of the first child,
- poor understanding of the French language.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tranexamic acid
intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
|
After the routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the woman within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped.
|
Placebo Comparator: Chloride solution
sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL).
|
After a routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes afterbirth), slowly (over 30-60 seconds), once the cord has been clamped.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
postpartum hemorrhage
Time Frame: day 2
|
Incidence of PPH defined by a calculated blood loss > 1000mL [Calculated estimated blood loss = estimated blood volume × (preoperative Ht - postoperative Ht)/preoperative Ht (where estimated blood volume (mL) = weight (Kg) × 85)] or red blood cell transfusion up to day 2 postpartum.
Preoperative Ht will be the most recent Ht within one week before delivery.
Postoperative Ht will be measured at D2
|
day 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mean calculated blood loss > 500mL
Time Frame: day 2
|
day 2
|
|
mean calculated blood loss > 1500mL
Time Frame: day 2
|
day 2
|
|
total mean calculated blood loss
Time Frame: day 2
|
day 2
|
|
mean gravimetrically estimated blood loss
Time Frame: 6 hours
|
by measuring the suction volume and swab weight; proportion of women requiring supplementary uterotonic treatment including sulprostone
|
6 hours
|
incidence of postpartum transfusion
Time Frame: day 2
|
day 2
|
|
Mean or median number of units of red blood cells transfused
Time Frame: day 2
|
day 2
|
|
incidence of arterial embolisation or emergency surgery for PPH
Time Frame: 3 months
|
3 months
|
|
mean peripartum change in haemoglobin
Time Frame: day 2
|
difference between the most recent Hb within one week before delivery and at day 2 postpartum
|
day 2
|
mean peripartum change in hematocrit
Time Frame: day 2
|
difference between the most recent Ht within one week before delivery and at day 2 postpartum
|
day 2
|
heart rate
Time Frame: 15, 30, 45, 60 and 120 minutes after delivery
|
bpm
|
15, 30, 45, 60 and 120 minutes after delivery
|
diastolic blood pressure
Time Frame: 15, 30, 45, 60 and 120 minutes after delivery
|
mmHg
|
15, 30, 45, 60 and 120 minutes after delivery
|
systolic blood pressure
Time Frame: 15, 30, 45, 60 and 120 minutes after delivery
|
mmHg
|
15, 30, 45, 60 and 120 minutes after delivery
|
number of participants with nausea reported by caregivers
Time Frame: 6 hours
|
6 hours
|
|
number of participants with vomiting reported by caregivers
Time Frame: 6 hours
|
6 hours
|
|
number of participants with phosphenes reported by caregivers
Time Frame: 6 hours
|
6 hours
|
|
number of participants with dizziness reported by caregivers
Time Frame: 6 hours
|
6 hours
|
|
creatinemia
Time Frame: day 2
|
micromol/L
|
day 2
|
urea
Time Frame: day 2
|
g/L
|
day 2
|
prothrombin time (PT)
Time Frame: day 2
|
day 2
|
|
aspartate transaminase
Time Frame: day 2
|
IU/L
|
day 2
|
alanine transaminase
Time Frame: day 2
|
IU/L
|
day 2
|
total bilirubin
Time Frame: day 2
|
micromol/L
|
day 2
|
total fibrinogen
Time Frame: day 2
|
g/L
|
day 2
|
number of participants with deep venous thrombosis confirmed by paraclinical exams
Time Frame: within twelve weeks after the delivery
|
within twelve weeks after the delivery
|
|
number of participants with pulmonary embolism confirmed by paraclinical exams
Time Frame: within twelve weeks after the delivery
|
within twelve weeks after the delivery
|
|
number of participants with myocardial infarction confirmed by paraclinical exams
Time Frame: within twelve weeks after the delivery
|
within twelve weeks after the delivery
|
|
number of participants with any thrombotic event confirmed by paraclinical exams
Time Frame: within twelve weeks after the delivery
|
within twelve weeks after the delivery
|
|
seizure
Time Frame: within twelve weeks after the delivery
|
within twelve weeks after the delivery
|
|
renal failure
Time Frame: within twelve weeks after the delivery
|
defined by the need for dialysis
|
within twelve weeks after the delivery
|
women's satisfaction
Time Frame: day 2 and weeks 8 postpartum
|
assessed by a self-administered questionnaire
|
day 2 and weeks 8 postpartum
|
Provider-assessed clinically significant PPH
Time Frame: day 2
|
day 2
|
|
Hb drop > 2g/DL
Time Frame: day 2
|
day 2
|
|
Active prothrombin time (aPTT)
Time Frame: day 2
|
day 2
|
|
aspartate transaminase > 2N
Time Frame: day 2
|
day 2
|
|
alanine transaminase > 2N (day 2)
Time Frame: day 2
|
day 2
|
|
gravimetrically estimated blood loss > 500mL
Time Frame: day 2
|
day 2
|
|
gravimetrically estimated blood loss > 1000 mL
Time Frame: day 2
|
day 2
|
|
Shock
Time Frame: day 2
|
day 2
|
|
Transfer to Intensive Care Unit
Time Frame: twelve weeks after delivery
|
twelve weeks after delivery
|
|
Death from any cause
Time Frame: 42 days postpartum
|
42 days postpartum
|
|
supplementary uterotonic treatment
Time Frame: day 2
|
proportion of women requiring supplementary uterotonic treatment
|
day 2
|
iron sucrose perfusion
Time Frame: discharge from hospital
|
incidence of iron sucrose perfusion
|
discharge from hospital
|
mean gravimetrically estimated blood loss
Time Frame: at the end of the cesarean delivery
|
at the end of the cesarean delivery
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Sentilhes L, Senat MV, Le Lous M, Winer N, Rozenberg P, Kayem G, Verspyck E, Fuchs F, Azria E, Gallot D, Korb D, Desbriere R, Le Ray C, Chauleur C, de Marcillac F, Perrotin F, Parant O, Salomon LJ, Gauchotte E, Bretelle F, Sananes N, Bohec C, Mottet N, Legendre G, Letouzey V, Haddad B, Vardon D, Madar H, Mattuizzi A, Daniel V, Regueme S, Roussillon C, Benard A, Georget A, Darsonval A, Deneux-Tharaux C; Groupe de Recherche en Obstetrique et Gynecologie. Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. N Engl J Med. 2021 Apr 29;384(17):1623-1634. doi: 10.1056/NEJMoa2028788.
- Sentilhes L, Daniel V, Deneux-Tharaux C; TRAAP2 Study Group and the Groupe de Recherche en Obstetrique et Gynecologie (GROG). TRAAP2 - TRAnexamic Acid for Preventing postpartum hemorrhage after cesarean delivery: a multicenter randomized, doubleblind, placebo- controlled trial - a study protocol. BMC Pregnancy Childbirth. 2020 Jan 31;20(1):63. doi: 10.1186/s12884-019-2718-4.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2015/41
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Hemorrhage
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedPostpartum Haemorrhage | Immediate Postpartum HemorrhageFrance
-
University Hospital, Clermont-FerrandUnknownPostpartum Depression | Postpartum Hemorrhage | Postpartum Women | Postpartum Stress | Postpartum AnxietyFrance
-
ResQ Medical LtdNot yet recruitingPPH | Postpartum Hemorrhage \(PPH\) | Postpartum Hemorrhage \(Primary\)Kenya
-
Cairo UniversityUnknownHemorrhage, PostpartumEgypt
-
Columbia UniversityCompletedHemorrhage, PostpartumUnited States
-
Ain Shams Maternity HospitalUnknownHemorrhage PostpartumEgypt
-
Chelsea and Westminster NHS Foundation TrustCompleted
-
Megan LordThermaSENSE CorpCompletedHemorrhage | Vasoconstriction | Hemorrhage, PostpartumUnited States
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedImmediate Postpartum HemorrhageFrance
-
Gynuity Health ProjectsAga Khan Health ServicesCompletedPostpartum Hemorrhage (PPH)Afghanistan
Clinical Trials on Tranexamic Acid Injectable Solution
-
London School of Hygiene and Tropical MedicineRawalpindi Medical CollegeCompletedPregnancy, High RiskPakistan, Zambia
-
Lancaster General HospitalActive, not recruitingHip FracturesUnited States
-
St. Olavs HospitalAleris HelseCompletedBleeding | Surgical WoundNorway
-
Nick EmanueleWithdrawnOrthognathic Surgery | Tranexamic AcidCanada
-
Mount Sinai Hospital, CanadaRecruiting
-
Instituto Nacional de Traumatologia e OrtopediaCompletedBlood Loss, Surgical | Hip Replacement | Tranexamic Acid Adverse ReactionBrazil
-
Population Health Research InstituteNot yet recruitingChronic Kidney Diseases | Bleeding | Surgery | Acute Kidney Injury
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health... and other collaboratorsCompletedTraumatic Brain InjuryUnited States, Canada
-
Nikola MatejcicUniversity orthopaedic and trauma hospital Lovran; University of Rijeka, The... and other collaboratorsCompletedShoulder Injuries | Rotator Cuff Tears | Hemorrhage, SurgicalCroatia
-
University Hospital Hradec KraloveCompletedRobotic-assisted Radical ProstatectomyCzechia